Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Super Six buy/sell calls for August 23

      Rajesh Jain of Religare Securities sugests buying NMDC with a target of Rs 124 and Cipla with a target of Rs 410.

    • Super Six: Top chart picks for August 16

      Manas Jaiswal of manasjaiswal.com recommends buying Dish TV India with a target of Rs 52 and NMDC with target of Rs 120.

    • Buy Cipla; target Rs 440-450: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Cipla as the stock may touch Rs 440-450 from current levels.

    • Macquarie upgrades Cipla after Q1 earnings

      Macquarie upgrades Cipla Ltd to "outperform" from "neutral" and raises its target price to 480 rupees from 400, saying the drugmaker's April-June earnings were "significantly above" their estimates.

    • Buy Cipla; sell Sun Pharma, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cipla and advises selling Sun Pharmaceutical Industries.

    • Cipla may test Rs 430, says SP Tulsian

      SP Tulsian of sptulsian.com feels that Cipla may test Rs 430 in near term. "The results will really be a trigger for Sun Pharma and in this series expect a price of Rs 545 in it," he adds.

    • Prefer Cipla in pharma space: Gopi Suvanam

      Gopi Suvanam, Founder of InvestWorks is of the view that Cipla can be a good investment in the pharma space.

    • Buy Cipla; target of Rs 425: Gopi Suvanam

      Gopi Suvanam of InvestWorks recommends buying Cipla with a target of Rs 425 and stop loss of around Rs 390.

    • Hold Sun Pharma, book profits on Lupin now: AnandRathi

      Rathi recommends booking profit in Lupin at current valuations. He has a neutral rating and a ‘hold‘ on the Sun Pharma stock because there are several triggers which can drive the earning surprise positively

    • Check out: Short term picks by market experts

      Sharmila Joshi of Peerless Securities recommends buying Tech Mahindra with an intraday target of Rs 1105.

    • Buy HCL Tech, Infosys, Wipro: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com says buy HCL Techologies, Infosys and Wipro.

    • HCL Tech, Sun Pharma, Ceat are good buys: Sharmila Joshi

      HCL is the only IT company that has gained from rupee depreciation and Sun Pharma can see a 10-15 percent kind of an upside from current levels

    • Buy HCL Technologies, Cipla: Amit Trivedi

      Amit Trivedi, Co-Founder of Investworks.in recommends to go long on HCL Technologies at around Rs 800.

    • Buy Cipla, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the opinion that one may get into Cipla as a small rally has started.

    • Check out: Top stock ideas by top 3 experts

      According to Ambareesh Baliga of Edelweiss Financial Services, one can buy Reliance Infrastructure. "This stock can move up to levels of about Rs 511-515, "he adds.

    • Don't buy Sun Pharma, Dr Reddys, Cipla: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com said he would not be a buyer in Sun Pharmaceuticals, Dr Reddys Laboratories and Cipla.

    • Prefer Glenmark, Aurobindo, Cipla over Ranbaxy: SP Tulsian

      SP Tulsian of sptulsian.com advises to prefer Glenmark Pharma, Aurobindo Pharma or Cipla over Ranbaxy Labs.

    • Citi view: How pharma sector is looking post Q4 debacle

      Prashant Nair of Citi India told CNBC-TV18 that the pharma sector's valuations in current market downturn situation has held up well. He presents his views on buzzing stocks from the sector.

    • Upbeat on Dr Reddys Labs, Sun Pharma, Cipla: Sukhani

      Sudarshan Sukhani of s2analytics.com says he is upbeat on Dr Reddys Labs, Sun Pharmaceutical and Cipla.

    • Sell ONGC, United Phosphorous; buy Cipla: Monal Desai

      Monal Desai of Sunidhi Securities advised selling ONGC and United Phosphorous. One can buy Cipla, he added.

    • Dr Reddys Labs, Cipla look attractive: Sukhani

      Dr Reddys Labs and Cipla are looking attractive at current levels. One can avoid Ranbaxy Labs, says Sudarshan Sukhani of s2analytics.com.

    • Hold Cipla, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com advised holding Cipla. He feels the stock will cross Rs 400.

    • Hold Cipla, Sun Pharma best stock to own: Sukhani

      According to Sudarshan Sukhani of s2analytics.com, Cipla is a good opportunity for long term. He advised holding the stock.

    • Cipla may rally 6-8%, says Manoj Murlidharan

      According to Manoj Murlidharan Vayalar of IIFL, Cipla may rally 6-8% from current levels.

    • Buy Cipla on every correction, advises Sukhani

      According to Sudarshan Sukhani of s2analytics.com one can buy Cipla on every decline, as the stock is expected to rally from current levels.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347